Skip to content
MarketScale
‹ Back to IndustriesSciences

Semi-Living Cyborg Cells Generate Hope Within the Scientific Medical Community

Did James Cameron see the future back in 1984? The Terminator may have been a cyborg piece of science fiction, but still, one portion of that movie is coming to life in the form of semi-living cyborg cells through a complex chemical process developed by scientists to mimic living cells without being able to divide…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By James Kent · Andrew AijianBiomedical EngineeringCyborg CellsDecibio
Share

Key takeaways

01

Did James Cameron see the future back in 1984?

02

The Terminator may have been a cyborg piece of science fiction, but still, one portion of that movie is coming to life in the form of semi-living cyborg cells through a complex chemical process developed by scientists to mimic living cells without being able to divide…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

Did James Cameron see the future back in 1984? The Terminator may have been a cyborg piece of science fiction, but still, one portion of that movie is coming to life in the form of semi-living cyborg cells through a complex chemical process developed by scientists to mimic living cells without being able to divide and grow.

“The cyborg cells are programmable, do not divide, and preserve essential cellular activities and gain non-native abilities,” said biomedical engineer Cheemeng Tan from the University of California, Davis.

Biomedical advancements, such as the use of AI and cell therapy, bring with them the potential for myriad applications. One such promising application is the use of cyborg cells in oncology. Lab testing on tissue samples is underway, and the hope is cyborg cells could one day be used to deliver drugs to specific parts of the body.

Where might this technology take science in the coming years? Stephane Budel, Ph.D., a Founding Partner at DeciBio, and Andrew Aijian, Ph.D., a Partner at DeciBio, a strategy and market intelligence company for the precision medicine industry, provided some clues.

Stephane and Andrew’s Thoughts

This is a very exciting paper. The advance of cyborg cells can have several therapeutic applications. A clear one is in oncology. There has been a lot of exciting development recently with CAR Ts. And people are discussing is it going to be autologous cells that come from the patient or allogeneic cells that would be easier to work with, where you would have like a massive batch of cells that you can use.

And there is now a third type of cells you could use: cyber cells. And in this case, you add synthetic polymers. The cells retain a number of functions, but they stop dividing. You can imagine people starting to be looking at a variety of different types of polymers and a variety of different types of synthetic pathways that they do to address cancer cells and beyond.” – Budel

Yeah, this is the first I’ve been exposed to cyborg cells. The first I’m hearing of it. And I think what will be interesting is to see how this approach gets applied to different cell types; bacterial cells, human cells, cells with different functionalities, et cetera. And you can sort of really start to explore a vast space of possibilities and how you can use these types of cells for health applications, synthetic biology, industrial applications, especially if you can introduce non-native capabilities. In the paper, they cited the ability of these cells to be more resistant to peroxide environments, which has implications in industrial applications.

There’s sort of a huge space of functionalities and capabilities that you can explore. And I’m sure that researchers will be spending a lot of time optimizing the cells and the conditions to create many novel functionalities.” – Aijian

Something we discussed as well is the need for these cells to actually evade the immune system. And there is certainly something that you can engineer in these cells as well that will be important if you want to inject them back into humans to treat virus conditions.” – Budel

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

JK
James KentPodcast Host and Content Creator

Dependable leader and Podcaster with more than 12 years of results-oriented brand marketing and agency management experience including a broad range of competencies: Adaptive communication and presentation skills. A manager who coaches, mentors and leads. Ability to successfully work cross-functionally within every level of an organization. Strong focus on innovative marketing solutions. Outstanding client relationship building and strategic account management support. Thrives in fast-paced environments with multiple deliverables. Podcast host and content creator.

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Lab automation ROI hinges on integration, not instrument sensitivity claims

Lab automation ROI hinges on integration, not instrument sensitivity claims

At ADLM 2026, Waters and LabCollector delivered a clear message for lab leaders: the limiting factor in automation is often integration, not hardware. Waters introduced the Xevo TQ Absolute XR IVD mass spectrometer and is positioning it at “5x greater sensitivity” versus in-class instruments, according to SelectScience, but that advantage only carries through if sample prep, calibration and QA, middleware rules, and LIMS result review can keep pace. In parallel, LabCollector announced an AI Co-Scientist feature set for natural-language search, knowledge retrieval, and AI-assisted content creation inside ELN and LIMS workflows, also reported by SelectScience, shifting attention from pipetting speed to retrieval, approval, permissions, and versioning in systems that sit on the documentation path. The Scientist’s overview of semi-automated versus fully automated approaches reinforces the point: labs can automate in modules, but they have to run automation as one system.

  • 01The bottleneck in automation is often the handoff, instrument to middleware to LIMS, so sensitivity and throughput gains depend on interfaces and downstream review as much as the instrument spec.
  • 02Waters’ “5x greater sensitivity” positioning and LabCollector’s AI Co-Scientist both point to integration work, sample prep, calibration and QA, middleware rules, and LIMS result review, as the gating factor for ROI.
  • 03As ELN/LIMS add conversational search and AI-assisted content creation, speed gains move from pipetting to retrieval, approval, permissions, and versioning inside systems that sit in regulated or audited workflows.

Sep 3, 2026

AeroVironment to co-design three autonomous helicopters for NASA's SkyFall Mars mission

AeroVironment to co-design three autonomous helicopters for NASA's SkyFall Mars mission

AeroVironment’s MacCready Works has been contracted to build three autonomous Mars helicopters for NASA's SkyFall mission. This development highlights the company's capabilities in aerospace-grade autonomy and avionics integration. The project shows a strong connection between aerospace and defense industries in terms of supply chain management.

  • 01AeroVironment is co-designing and co-manufacturing three autonomous helicopters for NASA's SkyFall Mars mission with JPL.
  • 02SkyFall will use a 'SkyFall maneuver' where three helicopters are released from a carrier spacecraft, separate, deploy, descend, and land under their own power, avoiding a dedicated lander or host rover.
  • 03AeroVironment leads rotor systems, airframes, structures, avionics integration, and payload provisions, while JPL leads the power system, electronics, algorithms, and software.

Aug 29, 2026

Telehealth "digital waiting rooms" are turning into premium pharma ad slots

Telehealth "digital waiting rooms" are turning into premium pharma ad slots

Pharmaceutical companies are increasingly using telehealth digital waiting rooms as prime advertising slots. These virtual spaces offer unique opportunities for pharma brands to engage patients before and after their virtual care visits. The trend is driven by fresh data on patient attention and strategic execution by agencies.

  • 01Pharmaceutical brands are using digital waiting rooms in telehealth platforms as premium ad slots.
  • 02New patient-attention data enhances pharma media plans for virtual care settings.
  • 03Virtual waiting rooms allow targeted patient engagement before and after healthcare consultations.

Aug 29, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

JK
James Kent

Podcast Host and Content Creator

Dependable leader and Podcaster with more than 12 years of results-oriented brand marketing and agency management experience including a broad range of competencies: Adaptive communication and presentation skills. A manager who coaches, mentors and leads. Ability to successfully work cross-functionally within every level of an organization. Strong focus on innovative marketing solutions. Outstanding client relationship building and strategic account management support. Thrives in fast-paced environments with multiple deliverables. Podcast host and content creator.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512